NEW YORK, Oct. 6, 2016 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Fusion Pharm, Inc. ("Fusion Pharma" or the "Company") (OTCMKT: FSPM). Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at email@example.com or 212-697-6484.
The investigation concerns whether Fusion Pharma and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On September 16, 2016, the U.S. Securities and Exchange Commission announced fraud charges against Fusion Pharm and its CEO, Scott M. Dittman, for deceiving shareholders by boasting Company revenues for supposed sales of PharmPods by round-tripping money from illegal stock sales by unknown affiliates.
If you are aware of any facts relating to this investigation, or purchased shares of Fusion Pharma, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/fspm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-fusion-pharm-inc-fspm-300340757.html
SOURCE Bronstein, Gewirtz & Grossman, LLC